Home >> Industry News >> Product News
Product News
  • Also available via:

Next Google Glass Might Be Monocle PDF
Submit Your News
Product News
Monday, 30 November 2015

Google Glass - monocle patentGoogle Glass may not have been a success, but the company is still trying to make a wearable gadget that people actually want to buy. According to a patent the company was granted recently, the eyewear gadget might be a monocle.

The device appears to rest on one side of the face, tucking over one ear with the display perched just above the eye. Images are included with documentation for the new patent, titled "Wearable Device with Input and Output Structures." The patent describes a device that could adjust to each user's head and recall that configuration for later use. The device would offer a heads-up display for playing video that could even be viewable in the other eye via a prism.

Seiko Optical Introduces 3D Printed Sports Eyewear Collection PDF
Submit Your News
Product News
Thursday, 05 November 2015

XchangerSeiko Optical Europe has collaborated with 3D printing service company Materialise in designing and manufacturing an additively manufactured collection of sports eyewear. The eyewear collection, called Xchanger, introduced at the leading optics fair Silmo 2015 in Paris and made in collaboration with Hoet Design Studio and Materialise Engineering Services, was awarded the Silmo d’Or for excellence in optical innovation in the Sport Equipment Category.

With the new Seiko Xchanger collection of sports eyewear, Seiko offers sports enthusiasts the ability to combine performance, comfort and aesthetics, through eyewear that features functionality and customizability beyond that of regular frames thanks to the engineering and design freedom of 3D Printing. In order to guarantee the quality and repeatability demanded, the Seiko Xchanger collection is manufactured on dedicated machines tuned specifically for 3D printing eyewear.

Allergan Expands Dry Eye Portfolio PDF
Submit Your News
Product News
Thursday, 22 October 2015

Refresh OptiveAllergan recently announced the launch of the over-the-counter artificial tear REFRESH OPTIVE® Gel Drops, a new aqueous gel expertly designed for patients who need or desire a more viscous artificial tear option to relieve their Dry Eye symptoms. From REFRESH®, the creators of the number one doctor recommended brand of artificial tears, new REFRESH OPTIVE® Gel Drops are formulated with Glycerin and a unique blend of the active ingredient CMC which binds to the eye surface to provide long-lasting relief from Dry Eye discomfort.

An estimated 25 million people in the United States suffer from Dry Eye symptoms, including irritation, blurred vision, sensitivity to light, burning, stinging, dryness and excessive tearing. In a multicenter, double-masked, randomized study, Dry Eye patients (n=94) using REFRESH OPTIVE® Gel Drops showed a statistically significant reduction in symptoms at day 30. The innovative Gel Drops formula delivers a shear-thinning effect that spreads quickly and evenly over the eye surface to relieve Dry Eye symptoms while creating a soothing shield to protect the eye surface from hypertonic stress.

As the latest addition to REFRESH OPTIVE® product line, REFRESH OPTIVE® Gel Drops are a part of Allergan's charitable program REFRESH AMERICA to supply America's heroic first responders with free eye drops. For every purchase of a package in the REFRESH OPTIVE® product line between 8/1/15-7/31/16, Allergan guarantees a minimum product donation with an approximate retail value of US$250,000. REFRESH OPTIVE® Gel Drops is available in 10 mL multi-dose bottles and can be found nationwide at various retail locations where over-the-counter eye drops are sold.

IPRO Introduces Innovative Eye Examination System at Silmo PDF
Submit Your News
Product News
Tuesday, 06 October 2015

PASKAL 3DAt the recently held Silmo Paris exhibition, German company IPRO introduced its innovative eye examination system PASKAL 3D. PASKAL 3D is a refraction system which enables the optometrist to carry out the complete monocular refraction under binocular conditions. During the whole examination, the patient sees separate images for the right and left eye, the images being separated by circular polarisation. This separation is done in the phoropter and the trial frame via special filters. A 3D-monitor is used to display the optotypes, separated line by line via circular polarisation.

The solution enables the optometrist to carry out the refraction in unprecedented quality and speed. Up to now, refraction meant to test one eye first, with the other covered, then the other way round, and finally, a few tests for both eyes. PASKAL 3D simplifies that process considerably using the latest 3D-technology, and also gives more accurate results than the old system. During the whole test, the patient can relax, looking at a nice scenery, and doesn't notice which of the images are offered to the right eye, and which are offered to the left eye.

IPRO received a nomination for the Silmo d'Or for its PASKAL 3D system at the recent Silmo Paris exhibition.

For more information goto:

Rare Blindness Disease Drug Approved in Europe PDF
Submit Your News
Product News
Wednesday, 23 September 2015

Swiss specialty pharmaceutical company Santhera Pharmaceuticals has recently announced that the European Commission (EC) has granted marketing authorization for Raxone® as the first approved medicine available in all 28 member states of the European Union (EU), Norway, Iceland and Liechtenstein for the treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON). This rare condition is an inherited mitochondrial disease which if untreated usually leads to rapid, profound and permanent blindness in otherwise healthy patients.

"Our data demonstrate that Raxone treatment can prevent patients from further vision loss and can promote clinically relevant recovery of vision," said Thomas Meier, PhD, Chief Executive Officer of Santhera. "The European approval of Raxone as an efficacious treatment for LHON and as the first approved medication for a mitochondrial disease is a major milestone for Santhera as it marks our transition to a pharmaceutical company with a product on the market. I personally want to thank the team that achieved this tremendous success and the patients and doctors who supported our clinical development program over the past years. We will now ensure patients have a rapid access to Raxone, with immediate availability in some European countries."

"Raxone represents a major breakthrough in mitochondrial disease treatment, and its approval paves the way for patients with LHON to be treated and to achieve a meaningful improvement of their visual acuity," said Thomas Klopstock, MD, Professor for Neurology at the University of Munich, LHON researcher and coordinator of the German network for mitochondrial disorders, mitoNET. "LHON is a particularly devastating condition because sufferers, who are otherwise healthy and often young, rapidly become bilaterally blind within a few months. Most will remain permanently blind if untreated."

Raxone is an oral medication authorized at a daily dose of 900 mg (given as 2 tablets three times a day with food), for the treatment of visual impairment in adolescent and adult patients with LHON. Treatment should be initiated and supervised by a physician with experience in LHON. Efficacy data come from Santhera's randomized, placebo-controlled RHODOS trial and from the open label Expanded Access Program, which together have demonstrated that vision loss can be mitigated or reversed in patients treated with Raxone.

Novartis Launches Smart Watch App for People with Vision Loss PDF
Submit Your News
Product News
Friday, 10 July 2015

Smart Watch appNovartis Pharmaceuticals announced the release of new features for its ViaOpta applications, and the extension for use with smart watches. The discreet, hands-free nature of using ViaOpta app with wearable devices, such as Apple Watch and Android Wear, provides users with an experience that seamlessly fits into their existing routines allowing those with visual impairments to navigate daily life with even greater ease.

Real-World Patient Benefits
“With the help of ViaOpta apps, people with impaired vision can do things such as walk to a nearby café, go to the pharmacy, and pick up their grandchildren at the kindergarten–helping to increase confidence and independence and maintaining discretion,” explains Ian Banks, Chair, The European Forum Against Blindness (EFAB).

ViaOpta Nav is the first turn-by-turn navigation app available for a wearable device designed specifically for visually impaired people, providing voice guidance and vibration settings, which alert the user to upcoming intersections and landmarks. The users can ask for their exact position, add waypoints to a calculated route, and find nearby destinations or landmarks and save them as favorites. Users and their caretakers can also share and access a person’s exact location. 

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 48